Elbonix 50 mg contains Eltrombopag, an oral thrombopoietin receptor agonist used to manage conditions associated with low platelet counts (thrombocytopenia). It is designed to stimulate platelet production in the bone marrow, thereby reducing the risk of bleeding and improving patient outcomes in selected hematological disorders. Elbonix 50 mg offers an effective, non-invasive treatment option with convenient oral administration.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Active ingredient: Eltrombopag 50 mg

• Dosage form: Oral tablet

Therapeutic Class

• Thrombopoietin (TPO) receptor agonist

• Hematopoietic agent

Mechanism of Action

Eltrombopag works by binding to and activating the thrombopoietin receptor (c-Mpl) on hematopoietic stem and progenitor cells in the bone marrow. This activation stimulates the proliferation and differentiation of megakaryocytes, leading to increased platelet production. Unlike platelet transfusions, Elbonix 50 mg supports the body’s natural platelet synthesis, making it suitable for long-term disease management under medical supervision.

Indications

Elbonix 50 mg is indicated for the treatment of:

• Chronic Immune Thrombocytopenia (ITP) in adult patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy

• Severe Aplastic Anemia, in patients who are refractory to immunosuppressive therapy

• Thrombocytopenia associated with chronic hepatitis C, to allow initiation and maintenance of interferon-based therapy, where applicable

Dosage and Administration

• The dose of Elbonix 50 mg is individualized based on platelet response and clinical condition.

• Tablets should be taken orally once daily, preferably on an empty stomach.

• It should be taken at least 2 hours before or 4 hours after products containing polyvalent cations such as calcium, iron, magnesium, aluminum, or zinc.

• Treatment and dose adjustments must be guided by a qualified healthcare professional with regular monitoring of platelet counts.

Benefits and Features

• Oral therapy that avoids the need for frequent platelet transfusions

• Helps maintain platelet counts within a safer target range

• Reduces the risk of bleeding complications

• Suitable for chronic use under careful medical supervision

• Supports improved quality of life in patients with thrombocytopenic disorders

Precautions and Warnings

• Liver function tests should be monitored regularly, as Eltrombopag may cause elevations in liver enzymes.

• Use with caution in patients with hepatic impairment.

• There is a potential risk of thromboembolic events if platelet counts become excessively high.

• Elbonix 50 mg should be used during pregnancy or breastfeeding only if clearly advised by a physician.

• Patients should inform their healthcare provider about all medications and supplements they are taking.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common side effects may include nausea, diarrhea, headache, fatigue, and abnormal liver function tests. Serious adverse effects are uncommon but may include hepatotoxicity or thrombotic events, requiring immediate medical evaluation.

Storage

• Store below 30°C

• Protect from light and moisture

• Keep out of reach of children

Elbonix 50 mg is a clinically proven option for managing thrombocytopenia by enhancing natural platelet production. When used appropriately under medical guidance, it provides effective and sustained platelet support in eligible patients.